Key Laboratory of Cardiovascular & Cerebrovascular Medicine, School of Pharmacy, Nanjing Medical University, Nanjing 211166, China.
Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
Biomed Pharmacother. 2020 Oct;130:110496. doi: 10.1016/j.biopha.2020.110496. Epub 2020 Jul 15.
The molecular mechanisms underlying autism spectrum disorder (ASD) remain elusive, which limits the management options available in the clinic. Accumulating evidence indicates that the pineal gland/melatonin system is associated with the progression of ASD. Here, we review recent advances in our understanding of various mechanisms involving pathological process of ASD, including the abnormal breakdown of melatonin synthesis, the disturbance of intracellular MTNR1A signaling, the effects exerted by melatonin on hippocampal protein serine/threonine kinases, and immune dysregulation/inflammation during ASD. We believe that an in-depth understanding of the interplay between the action of the melatonin system and the onset of autism could promote the development of novel therapeutic strategies against ASD. We anticipate that targeting the neurotransmitters upstream pathway and downstream of melatonin in brain will lead to potential therapeutic treatment for ASD.
自闭症谱系障碍(ASD)的潜在分子机制仍难以捉摸,这限制了临床可用的治疗选择。越来越多的证据表明,松果腺/褪黑素系统与 ASD 的进展有关。在这里,我们回顾了我们对涉及 ASD 病理过程的各种机制的理解的最新进展,包括褪黑素合成异常分解、细胞内 MTNR1A 信号的干扰、褪黑素对海马蛋白丝氨酸/苏氨酸激酶的影响以及 ASD 期间的免疫失调/炎症。我们相信,深入了解褪黑素系统的作用与自闭症的发病之间的相互作用,可以促进针对 ASD 的新治疗策略的发展。我们预计,针对大脑中褪黑素的神经递质上游途径和下游途径将为 ASD 提供潜在的治疗方法。